Ratings Pfizer Limited Bombay S.E.

Equities

PFIZER

INE182A01018

Delayed Bombay S.E. Other stock markets 05:10:59 2024-04-24 am EDT			5-day change	1st Jan Change
4,138 ^INR	-0.17%		+0.75%	-3.06%

Apr. 02	Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer	CI
Apr. 02	Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director Finance	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.86 times its estimated earnings per share for the ongoing year.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PFIZER LIMITED	-3.06%	2.28B	C
ELI LILLY AND COMPANY	+27.92%	672B	C+
NOVO NORDISK A/S	+26.86%	570B	B
JOHNSON & JOHNSON	-4.59%	360B	C+
MERCK & CO., INC.	+16.38%	321B	B-
ABBVIE INC.	+9.39%	300B	C+
ASTRAZENECA PLC	+7.42%	217B	B+
NOVARTIS AG	+5.41%	199B	B-
ROCHE HOLDING AG	-8.63%	204B	A+
PFIZER, INC.	-8.58%	149B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes